Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 486 participants.

Also called NCT06362746

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 486 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06362746
Other papers using this trial's data
  • Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE Journal of thrombosis and haemostasis : JTH, 2025-02 DOI, PubMed 39454884

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06362746. Randomized; double masking; primary purpose treatment. Start 2024-05-23 (actual); primary completion 2028-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
Intervention (Drug)
Non-immunogenic recombinant staphylokinase
Intervention (Drug)
Placebo
Lead sponsor
Supergene, LLC (class: industry)

Record details

Record id
cardio:ct-nct06362746
Content hash
10c78d8643e6605f88a95508b8028a884242775d04d3c33f5c7c943917e0523f